Array BioPharma Selects Medidata Rave(R) as Enterprise-Wide Electronic Data Capture Solution.

Company Chooses Medidata Due to Superior Product Functionality and Corporate Vision

NEW YORK -- Medidata Solutions today announced that Array BioPharma has chosen Medidata Rave[R] as its enterprise-wide electronic data capture (EDC) solution. Over a period of three years, Array BioPharma plans to conduct more than 20 studies using Medidata Rave for Phase I and II trials in the therapeutic areas of oncology and inflammation.

Established in 1998, Array BioPharma seeks to be the most efficient inventor of therapeutic products in the pharmaceutical industry. The biopharmaceutical company focuses specifically on the discovery, development and commercialization of orally active drugs to address significant unmet clinical needs. In 2006, Array's IT department undertook the task of putting EDC in place as a critical component to running clinical trials. Array BioPharma comprised a list of key EDC providers and quickly narrowed it down to a group of five players. After examining each company's application services provider (ASP) model, Array selected two vendors for a technical product analysis.

Array's scientific computing group then conducted a year-long evaluation with input from upper management, and Medidata Solutions was selected due to the company's superior product functionality. Specifically, Array was impressed with the single platform design of Medidata Rave for EDC and clinical data management, with its ability to easily pull data for a variety of reporting needs.

"Medidata Rave is an intuitive, easy to use solution - even for users who were new to the system. Using Rave, clinical research associates (CRAs) can access data and site information earlier and become better prepared for more productive site visits. In addition, Rave's ability to build forms electronically on our initial trials has resulted in improved protocol design for clinical study managers," said Jim Rizzi, senior director of computational technology at Array BioPharma. "We have been continually impressed with Medidata's corporate culture, the vision of the company's executives and the professionalism of its services team. We look forward to improved results by leveraging Rave as the center of our clinical process."

Array BioPharma plans to use Medidata service offerings to provide training and help desk support, hosting services and integrations as well as collaborations, integrating Rave into unique customer tools.

"Array BioPharma is an innovative, forward-thinking company that stays at the cutting edge of clinical trial development, and we are excited for the improvements Medidata Rave will bring to Array's clinical process," said Tarek Sherif, CEO of Medidata Solutions. "The company's enterprise-wide deployment of Medidata Rave speaks to the rapid acceptance of our technology within the mid-market and the ability of our team to successfully execute Rave deployments for sponsors of all sizes."

About Array BioPharma

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and inflammatory diseases. Our proprietary drug development pipeline includes clinical candidates that are designed to regulate therapeutically important target proteins and are aimed at large market opportunities. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas. For more information on Array, please go to www.arraybiopharma.com.

About Medidata Solutions Worldwide

Medidata Solutions helps the world's leading pharmaceutical, biotechnology, medical device and research organizations maximize the value of their clinical research investments. Innovative process design, technology and services streamline clinical trials by providing early visibility to reliable clinical data - the lifeblood of every research organization. Working with companies and institutions both large and small, Medidata Solutions helps clinical researchers safely accelerate the process of bringing life-enhancing treatments to market - on six continents and in more than 80 countries. Medidata Solutions brings significant value to its broad client base with deep clinical experience and expertise in more than 20 therapeutic areas, projects in Phase I, II, III, IV, registries and surveillance, and studies with thousands of investigators and tens-of-thousands of subjects. For more information, please visit www.mdsol.com.